Next Post
Structural Tuning of Vidofludimus for High-Efficacy NR4A Agonism
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer